Literature DB >> 7321094

Control of expression of the vaccinia virus thymidine kinase gene.

D E Hruby, L A Ball.   

Abstract

mRNA extracted from vaccinia virus-infected cells early after infection directs cell-free synthesis of enzymatically active viral thymidine kinase (Hruby and Ball, Virology, in press). We used this assay for a specific vaccinia virus mRNA to study the induction and repression of the viral thymidine kinase gene during infection of thymidine kinase-deficient L-cells. As observed previously by other workers, the synthesis of thymidine kinase occurred immediately after infection but was switched off after 4 h later. We observed similar kinetics of accumulation and shutoff under conditions where viral DNA synthesis and late gene expression were inhibited. Cell-free translation of mRNA from infected cells showed that the concentration of functional message for viral thymidine kinase reached a peak 3 to 4 h after infection and then decreased with a half-life of about 1 h. These kinetics indicated that significant levels of thymidine kinase mRNA persisted in cells which had stopped synthesizing the enzyme. Under conditions where late gene expression was inhibited, high concentrations of functional mRNA could be isolated from cells at late times after infection. On the basis of these results, we conclude that the repression of thymidine kinase expression is mediated at the translational level by one or more early or delayed early viral genes. Repression is accompanied by, but does not depend on, the inactivation or degradation of thymidine kinase mRNA, which is a late gene function.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7321094      PMCID: PMC256647     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  ISOLATION AND PROPERTIES OF VACCINIA MUTANTS DEFICIENT IN THYMIDINE KINASE-INDUCING ACTIVITY.

Authors:  D R DUBBS; S KIT
Journal:  Virology       Date:  1964-02       Impact factor: 3.616

2.  Translation of encephalomyocarditis virus RNA in reticulocyte lysates: kinetic analysis of the formation of virion proteins and a protein required for processing.

Authors:  D S Shih; C T Shih; D Zimmern; R R Rueckert; P Kaesberg
Journal:  J Virol       Date:  1979-05       Impact factor: 5.103

3.  Purification of vaccinia virus-induced thymidine kinase activity from [35S]methionine-labeled cells.

Authors:  S Kit; G N Jorgensen; A Liav; V Zaslavsky
Journal:  Virology       Date:  1977-04       Impact factor: 3.616

4.  Regulation of virus-induced deoxyribonucleases.

Authors:  B R McAuslan; J R Kates
Journal:  Proc Natl Acad Sci U S A       Date:  1966-06       Impact factor: 11.205

5.  Characterization and localization of the naturally occurring cross-links in vaccinia virus DNA.

Authors:  P Geshelin; K I Berns
Journal:  J Mol Biol       Date:  1974-10-05       Impact factor: 5.469

6.  Cell-free translation of early and late mRNAs selected by hybridization to cloned DNA fragments derived from the left 14 million to 72 million daltons of the vaccinia virus genome.

Authors:  H B Isle; S Venkatesan; B Moss
Journal:  Virology       Date:  1981-07-15       Impact factor: 3.616

7.  Vaccinia virus polypeptide synthesis: sequential appearance and stability of pre- and post-replicative polypeptides.

Authors:  T H Pennington
Journal:  J Gen Virol       Date:  1974-12       Impact factor: 3.891

8.  Intermolecular duplexes formed from polyadenylylated vaccinia virus RNA.

Authors:  R F Boone; R P Parr; B Moss
Journal:  J Virol       Date:  1979-04       Impact factor: 5.103

9.  Vaccinia virus replication. I. Requirement for the host-cell nucleus.

Authors:  D E Hruby; L A Guarino; J R Kates
Journal:  J Virol       Date:  1979-02       Impact factor: 5.103

10.  Transfer of thymidine kinase to thymidine kinaseless L cells by infection with ultraviolet-irradiated herpes simplex virus.

Authors:  W Munyon; E Kraiselburd; D Davis; J Mann
Journal:  J Virol       Date:  1971-06       Impact factor: 5.103

View more
  25 in total

1.  Antibodies directed against a synthetic peptide enable detection of a protein encoded by a vaccinia virus host range gene that is conserved within the Orthopoxvirus genus.

Authors:  S Gillard; D Spehner; R Drillien; A Kirn
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

2.  DNA sequences that regulate expression of a vaccinia virus late gene (L65) and interact with a DNA-binding protein from infected cells.

Authors:  J N Miner; D E Hruby
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

3.  Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge.

Authors:  E J Stott; L A Ball; K K Young; J Furze; G W Wertz
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

4.  Hydroxyurea-resistant vaccinia virus: overproduction of ribonucleotide reductase.

Authors:  M B Slabaugh; C K Mathews
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

5.  High-frequency homologous recombination in vaccinia virus DNA.

Authors:  L A Ball
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

6.  Mapping and identification of the vaccinia virus thymidine kinase gene.

Authors:  D E Hruby; L A Ball
Journal:  J Virol       Date:  1982-08       Impact factor: 5.103

7.  Fine structure analysis and nucleotide sequence of the vaccinia virus thymidine kinase gene.

Authors:  D E Hruby; R A Maki; D B Miller; L A Ball
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

8.  Isolation and genetic characterization of temperature-sensitive mutants of vaccinia virus WR.

Authors:  M J Ensinger
Journal:  J Virol       Date:  1982-09       Impact factor: 5.103

9.  Vaccinia virus induces ribonucleotide reductase in primate cells.

Authors:  M B Slabaugh; T L Johnson; C K Mathews
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

10.  Vaccinia virus thymidine kinase and neighboring genes: mRNAs and polypeptides of wild-type virus and putative nonsense mutants.

Authors:  G Bajszár; R Wittek; J P Weir; B Moss
Journal:  J Virol       Date:  1983-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.